Average and Maximum Heart Rate
Observed session intensity interpreted relative to movement mode, pace, elevation, altitude, duration, terrain, and prior load.
Biomarkers connect TrailGenic’s protocols to measured response and possible adaptation. Read heart rate, sleep, HRV, resting HR, and metabolic proxies beside the behavior, conditions, measurement method, and follow-up that produced them.
The original contribution is a measurement framework linked to TrailGenic sessions and longitudinal comparisons: context → behavior → response → recovery → possible adaptation → decision rule. Ella helps interpret those connections; a dashboard number alone is not a finding.
Recorded signals come from field instruments, wearables, or human reports. Identify the source, units, timing, protocol, missingness, and whether each value is measured, device-estimated, calculated, or inferred. These categories must not be merged.
Observed session intensity interpreted relative to movement mode, pace, elevation, altitude, duration, terrain, and prior load.
Garmin-estimated running VO₂ max progresses from 45 in S1–15 to 46 in S16–18 and 48 in S19–21: +6.7% from the opening value and +4.3% from 46. The 48 first appears September 10 and remains recorded through September 23. This upward aerobic-fitness signal is central to the longevity interpretation. Use the Running series explicitly: the Hiking VO2Max_Garmin field remains 46 throughout, and the workbook does not timestamp each Garmin recalculation. These are device estimates in mL/kg/min; the source fields are preserved separately.
Overnight context that may be relevant after altitude, travel, poor sleep, illness, or unusual strain.
Garmin estimates describing the character of an effort—not laboratory measurements of adaptation.
A wearable estimate interpreted alongside duration, terrain, altitude, mechanics, symptoms, and subsequent return.
All 40 hikes with paired measurements show breath acetone rising from start to finish, then falling by the next day. Medians are 2.2 → 7.05 → 2.0 ppm; the median within-hike rise is 5.1 ppm and median end/start ratio 3.62×. H29 has no paired ketone data. This is a repeated metabolic response across the field record. The measured variable is breath acetone in ppm; it is not a blood-ketone concentration.
Evaluate the recovery trajectory across comparable episodes. H1–20 → H21–41 shows average next-night sleep scores 59.8 → 63.7 and resting HR 61.7 → 60.0 bpm (n=19 → 20). H41 is included as one disrupted-sleep episode. Second-night sleep remains more variable, so the improvement is specifically next-night on average.
Preserve route, altitude, weather, temperature source, wind, surface, equipment, fueling, and hydration where recorded. Hiking analyzes these interacting conditions directly. Foundation protocols prioritize route consistency, while changing conditions remain potential confounders.
Fatigue, soreness, cognition, pain, illness, perceived exertion, and practical field judgment remain part of the record.
Distance, duration, gain, heart rate, load, altitude, environment, mechanics, metabolic context, and symptoms.
Sleep, HRV, resting heart rate, stress, soreness, fatigue, symptoms, and time—without converting one delta into proof.
The next relevant effort can support, refine, or contradict an interpretation while remaining observational.
| Earlier biomarker story | Current evidence | Treatment |
|---|---|---|
| Wheeler was the first positive-drift hike and a fatigue-reveal effort | Five positive-drift hikes preceded Wheeler; drift and pre-hike HRV correlated at r = +0.03 | Fatigue-reveal claim withdrawn |
| Pre-to-post HRV delta measured recovery cost | The delta correlated with its starting value at r = −0.738 | Derived metric retired |
| Pikes demonstrated recovery failure before performance | Low absolute HRV and difficult sleep context remain observations; the retired delta does not establish failure | Causal claim withdrawn |
| Negative drift independently certified cardiac efficiency | Whole-route drift is route-, pace-, terrain-, altitude-, temperature-, and recording-dependent | Retained as directional context |
The full 41-hike record supports cardiovascular adaptation at broadly maintained workloads. H1–20 → H21–41: average HR 127.2 → 124.2 bpm, maximum HR 155.7 → 150.0, distance 10.87 → 10.78 miles, elevation gain 4,176 → 4,034 feet, and moving time 259 → 260 minutes. H41 is included.
Next-night paired observations (n=19 → 20) show mean HRV change −6.7 → −2.8 ms, sleep-score change −12.9 → −2.5, and resting-HR change +2.6 → +1.7 bpm. These support improved average next-night response; starting values affect the deltas. Second-night sleep is more variable: mean score 70.0 → 63.2 (n=19 → 18), while absolute Day-2 HRV stays near 40 ms.
All 40 hikes with paired measurements show breath acetone rising from start to finish, then falling by the next day. Medians are 2.2 → 7.05 → 2.0 ppm; the median within-hike rise is 5.1 ppm and median end/start ratio 3.62×. H29 has no paired ketone data. This is a repeated metabolic response across the field record.
Autophagy remains a biological hypothesis within TrailGenic’s longevity method. Human exercise studies show activation of autophagy-related signaling in skeletal muscle, supporting a plausible cellular-maintenance pathway for repeated movement. TG’s breath-acetone series measures the metabolic response; it does not measure autophagic flux or its magnitude. Continued fasting and hiking are combined exposures in this record. Human skeletal-muscle studies: Møller et al. (2015), PMID 25678702; Schwalm et al. (2015), PMID 25957282.
Mount Baldy, Mount Wilson, San Jacinto, San Gorgonio, Baden-Powell, and the Icehouse Canyon network provide recurring environments for comparison across seasons, metabolic states, protocols, weather, and recovery histories.
TrailGenic interpretation rule · September 24, 2026: lead with the complete trajectory, then comparable route/load blocks, then the new episode. Connect each measure to its longevity-relevant domain. Interpret the full trajectory and comparable route or load blocks before the latest session. Preserve the established movement base; adjust a planned dose when repeated comparable responses, symptoms, or recovery trajectories support the change. A single disrupted night or episode does not establish a capacity ceiling. Change one major protocol variable at a time and retain follow-up.